Lung Cancer (NSCLC) — Deal Benchmarks & Valuation
Market Analysis
Lung Cancer (NSCLC) is one of the most actively transacted indications in oncology licensing. Phase 2 deals for lung cancer (nsclc) carry a median total deal value of $1.6B, with upfront payments ranging from $144M to $365M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Milestone structures for lung cancer (nsclc) deals allocate $345M to development milestones, $552M to regulatory milestones, and $483M to commercial milestones. Royalty rates range from 11.8% to 19.3% at the base tier, with tiered escalation reaching 15.8%-23.3% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for lung cancer (nsclc) licensing?
What royalty rates are standard for lung cancer (nsclc) deals?
How are lung cancer (nsclc) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.